Charlesson's News
11/11/2008:
Charlesson selected to receive two-year funding from Oklahoma EDGE
11/04/2008:
10/21/2008:
08/01/2008:
07/22/2008:
Charlesson scientist, Dr. Rafal Farjo, receives $241,000 Phase I SBIR grant from the National Institutes of Health to develop CLT-005 for Retinal Inflammation and Neovascularization
06/05/2008:
Mike Moradi, CEO of Charlesson, featured in The Oklahoman
05/22/2008:
Charlesson scientist, Dr. Ying Chen, receives $90,000 award from the Oklahoma Center for Advancement in Science and Technology to develop CLT-009 as a treatment for Age-Related Macular Degeneration
04/23/2008:
Charlesson scientist, Dr. Drew Wassel, receives $204,280 award from the Oklahoma Center for Advancement in Science and Technology to develop nanoparticle drug formulations
04/21/2008:
Ocular Biopharmaceutical Company Charlesson Announces $1.6MM in New Funding and Upcoming Presentations at The Association for Research in Vision and Ophthalmology
03/11/2008:
Charlesson scientist, Dr. Rafal Farjo, receives $1,388,000 Phase II SBIR grant from the National Insitutues of Health to develop CLT-004 for Diabetic Retinopathy and Age-Related Macular Degeneration.